中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2009年
6期
375-378
,共4页
韩刚%高江平%洪宝发%王晓雄%文载律%唐杰%张旭
韓剛%高江平%洪寶髮%王曉雄%文載律%唐傑%張旭
한강%고강평%홍보발%왕효웅%문재률%당걸%장욱
前列腺肿瘤%活组织检查%转录因子
前列腺腫瘤%活組織檢查%轉錄因子
전렬선종류%활조직검사%전록인자
Prostatic neoplasms%Biopsy%Transcription factor
目的 探讨前列腺穿刺标本中磷酸化信号传导与转录激活因子3(P-STAT3)表达在前列腺癌(PCa)早期诊断中的应用价值.方法采用免疫组织化学方法检测接受重复穿刺的PCa患者初次穿刺未检出癌的标本(29例)、重复穿刺确诊PCa时的癌灶标本(29例)、重复穿刺确诊PCa时的非癌灶标本(29例)以及良性前列腺增生(BPH)患者初次穿刺标本(29例)中P-STAT3的表达.统计学分析其与临床诊断的相关性及对PCa发生的预测作用.结果 P-STAT3在PCa患者癌灶标本、非癌灶标本及初次穿刺标本中阳性表达率分别为93.1%(27/29)、82.8%(24/29)和86.2%(25/29),在BPH标本中阳性表达率为10.3%(3/29),前三者的阳性率明显高于后者(X2=60.123,P=0.000);如以初次穿刺标本中P-STAT3表达阳性作为PCa的诊断标准,该方法的敏感性为86.2%,特异性为89.7%.结论 检测穿刺标本P-STAT3表达可以作为前列腺穿刺活检的辅助诊断方法,用于PCa的早期诊断,预测PCa的发生.
目的 探討前列腺穿刺標本中燐痠化信號傳導與轉錄激活因子3(P-STAT3)錶達在前列腺癌(PCa)早期診斷中的應用價值.方法採用免疫組織化學方法檢測接受重複穿刺的PCa患者初次穿刺未檢齣癌的標本(29例)、重複穿刺確診PCa時的癌竈標本(29例)、重複穿刺確診PCa時的非癌竈標本(29例)以及良性前列腺增生(BPH)患者初次穿刺標本(29例)中P-STAT3的錶達.統計學分析其與臨床診斷的相關性及對PCa髮生的預測作用.結果 P-STAT3在PCa患者癌竈標本、非癌竈標本及初次穿刺標本中暘性錶達率分彆為93.1%(27/29)、82.8%(24/29)和86.2%(25/29),在BPH標本中暘性錶達率為10.3%(3/29),前三者的暘性率明顯高于後者(X2=60.123,P=0.000);如以初次穿刺標本中P-STAT3錶達暘性作為PCa的診斷標準,該方法的敏感性為86.2%,特異性為89.7%.結論 檢測穿刺標本P-STAT3錶達可以作為前列腺穿刺活檢的輔助診斷方法,用于PCa的早期診斷,預測PCa的髮生.
목적 탐토전렬선천자표본중린산화신호전도여전록격활인자3(P-STAT3)표체재전렬선암(PCa)조기진단중적응용개치.방법채용면역조직화학방법검측접수중복천자적PCa환자초차천자미검출암적표본(29례)、중복천자학진PCa시적암조표본(29례)、중복천자학진PCa시적비암조표본(29례)이급량성전렬선증생(BPH)환자초차천자표본(29례)중P-STAT3적표체.통계학분석기여림상진단적상관성급대PCa발생적예측작용.결과 P-STAT3재PCa환자암조표본、비암조표본급초차천자표본중양성표체솔분별위93.1%(27/29)、82.8%(24/29)화86.2%(25/29),재BPH표본중양성표체솔위10.3%(3/29),전삼자적양성솔명현고우후자(X2=60.123,P=0.000);여이초차천자표본중P-STAT3표체양성작위PCa적진단표준,해방법적민감성위86.2%,특이성위89.7%.결론 검측천자표본P-STAT3표체가이작위전렬선천자활검적보조진단방법,용우PCa적조기진단,예측PCa적발생.
Objective To investigate the expression of Phosphorylated-signal transduction and activators of transcription 3 (P-STAT3) proteins in human prostate tissue from patients received re-peated biopsies. And consider the usefulness of detecting expression of P-STAT3 in early diagnosis of prostate cancer (PCA). Methods Fifty-eight patients (29 cases of PCA, and 29 cases of benign prostatic hyperplasia (BPH)) who had received repeated biopsies were involved in this study. Immu-nolabelling has been carried out on PCa patients' samples of cores from initially negative biopsies, typ-ical cores from cancer field, and other cores of the same batch biopsies showing no sign of prostate cancer. BPH patients' samples of cores from initial biopsies were set as control. All specimens were done immunohistochemistry stain with anti-P-STAT3 monoclonai antibody. The association of P-STAT3 expression in prostate tissues with the pathology result was evaluated. Results Compared with 10.3% in specimens of patients free of prostate cancer, the positive rate of anti-P-STAT3 stained in typical cores from cancer field, other cores of the same batch biopsies showing no sign of prostate cancer, and cores from initially negative biopsies, was 93.1 % (27/29), 82.8 % (24/29) and 86.2 % (25/29), respectively. There were significant differences of these values between former and laters' (X2=60.123,P=0.000). If P-STAT3 positive in tissue of initially biopsies was considered as the di-agnostic standard of prostate cancer, then it would show a relatively high sensitivity (86.2%) and specificity (89.7%). Conclusion IHC stain for P-STAT3 in prostate biopsy samples could be served as an adjunct to the current diagnostic approach to prostate biopsy for early diagnosis of pros-tate cancer.
